Agenda Discovery Week Month

Curated for Me

Test2LearnTM Pharmacogenomic Certificate Training Sandusky, OH

PGx101, LLC
Write a Review
Select your rating. ( ) ( ) ( ) ( ) ( )
Endorsed by Curators:
Nov 09 8:30AM - 4:30PM

Pharmacists: Earn a Certificate in Pharmacogenomics

Facilitating the training are Dan Krinsky, BS, MS, RPh and Sue Paul, RPh, PGx101 Co-Founders.

This program enables attendees to learn by using real genetic data in highly interactive exercises.

Each attendee will be offered an optional, personal, low-cost pharmacogenomic test. We highly recommend testing yourself so that you can experience the insights your patients will experience.

Earn 20 ACPE accredited continuing education credit hours

Activity Description

TheTest2LearnTMCommunity-basedPharmacogenomics Certificate Programteaches the principles of pharmacogenomics as well as its practical implications in disease states such as cardiology, oncology, neurology and infectious diseases, among others. It trains pharmacists to decipher genetic tests, translate that information, and make appropriate recommendations for the patient (including collection of DNA samples) interpretation of patient results, and counseling and collaboration with prescribers to help optimize patient medication regimens.
The 20-hour ACPE-accredited certificate program enables students to learn by using real genetic data in highly-interactive exercises with an optional activity for learners to undergo personal genomic testing.The Certificate Program is comprised of:

12 hours of home study

8 hours of live training

The target audience for the certificate program is pharmacists in all practice settings including community, ambulatory care, inpatient, professional associations, and academia. While the program is primarily designed for pharmacists, student pharmacists and non-pharmacists interested in pharmacogenomics are also welcome to complete the program.

Successful completion of the live seminar component will result in 8.0 contact hours of continuing pharmacy education credit.Successful completion of the self-study component involves passing the self-study assessment questions with a grade of 80 percent or higher and will result in 12.0 contact hours of continuing pharmacy education. Attendance and participation are required before obtaining CPE credit. Partial credit will not be awarded.

Learning Objectives
The pharmacist who completes the home-study and live components of this Pharmacogenomics Certificate Program should be able to:

  • Demonstrateunderstanding of basic genetic/genomic concepts and nomenclature
  • Describeadvances in scientific knowledge and technology, which have led to innovations in personalized medicine
  • Identifythe role of behavioral, social and environmental factors (lifestyle, socioeconomic factors, pollutants, among others) to modify or influence genetics in the manifestation of disease.
  • Compare and contrastdifferent PGx study designs.
  • Identifydrug- and disease-associated genetic variations that facilitate development of prevention and treatment strategies and appreciate there are differences in testing methodologies and are aware of the need to explore these differences in drug literature evaluation
  • Assesspredisposition to disease and selection of drug treatment by using family history
  • Describethe role of genetic factors in maintaining health and preventing disease
  • Assessthe difference between clinical diagnosis of disease and identification of genetic predisposition to disease (genetic variation is not strictly correlated with disease manifestation)
  • Recognizethat pharmacogenomic testing may also reveal certain genetic disease predispositions (e.g., the Apo E4 polymorphism)
  • Demonstrate an understandingof how genetic variation in a large number of proteins influences pharmacokinetics and pharmacodynamics related to pharmacologic effect and drug response
  • Use online resourcesto assign haplotypes and predicted drug response phenotypes from genetic data.
  • Describethe influence (or lack thereof) of ethnicity in genetic polymorphisms and associations of polymorphisms with drug response
  • Recognizethe availability of evidence-based guidelines that synthesize information relevant to genomic/pharmacogenomic tests and selection of drug therapy (e.g. Clinical pharmacogenomics implementation consortium)
  • Evaluatethe availability of genetic testing under FDA, CLIA, and DTC regulations.
  • Evaluate PGx test reports through group-based activities and role-playing to demonstrate the PGx knowledge/skill-based competencies
  • Createa step-wise decision-making process for the integration of PGx with clinical variables known to impact PK/PD to make appropriate PGx-based recommendations for patients and populations.
  • Listdrugs/clinical situations where PGx testing is likely to be most useful clinically
  • Identifythe potential physical and/or psychosocial benefits, limitations and risk of genomic/pharmacogenomic information for individuals, family members and communities, especially with genomic/pharmacogenomic tests that may relate to predisposition to disease
  • Describethe increased liability that accompanies access to detailed genomic patient information and maintain confidentiality and security
  • Definethe cost, costeffectiveness and reimbursement by insurers relevant to genomic or pharmacogenomic tests and test interpretation for patients and populations
  • Identifythe need to refer a patient to a genetic specialist or genetic counselor
  • Describeproper documentation of test results in electronic patient record
  • Adopta culturally sensitive and ethical approach to patient counseling regarding PGx test results
  • Demonstratepatient and provider communication about PGx testing and test results and counseling through group-based activities and role-playing
  • Evaluatedifferent business models to integrate PGx in various practice sites
  • Discussdifferent strategies to engage with local practitioners to optimize the delivery of PGx services prior to implementation
  • Review of safety procedures for handling biospecimens and proper mailing

The National Association of Chain Drug Stores is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The home study portion of the program is approved for 12contact hours and the live training is approved for8 contact hours of continuing pharmacy education credit. Credit is only awarded for completion of the entire 20contact hour program. Credit must be claimed within 60 days of completing the program.

Test2LearnTMCommunity-based Pharmacogenomics Certificate Program ACPE Universal Activity #0206-0000-19-012-B04-P.

Activity Type:Practice-based

Target Audience:Pharmacists in all practice settings

Release Date:June 13, 2019

Expiration Date:June 13, 2022


How can I contact the organizer with any questions?

Please email Sue at

What's the refund policy?

No refunds, but it is transferable

Is my registration fee or ticket transferable?

Yes, $100 administrative fee to make sure the attendee gets the proper credit.

Upcoming Events